Top Markets
Coin of the day
F-star Therapeutics, Inc. F-star Therapeutics, Inc.

F-star Therapeutics, Inc.

FSTX
株式のランク #21013
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated... F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to inventing tetravalent bispecific antibodies for the treatment of cancer, particularly within the field of immuno-oncology. The company's primary investigational product, FS118, is currently in a Phase 2 proof-of-concept trial, evaluating its efficacy in head and neck cancer patients who have acquired resistance to PD-1/PD-L1 therapies. F-star is also advancing FS222, a bispecific antibody designed to simultaneously target the costimulatory CD137 receptor and the inhibitory PD-L1 ligand, through its initial Phase 1 human clinical study. Moreover, two additional drug candidates, FS120 and SB 11285, are undergoing Phase 1 clinical evaluation for patients with advanced malignancies. Founded in 2002, F-star Therapeutics, Inc. has its corporate headquarters situated in Cambridge, United Kingdom.
株価
$7.12
最終同期: 2023-03-08
時価総額
$117.03M
変化(1日)
0.00%
変化(1年)
0.00%
GB
取引 F-star Therapeutics, Inc. (FSTX)

カテゴリー

F-star Therapeutics, Inc.(FSTX)の配当利回りの履歴
F-star Therapeutics, Inc.(銘柄コード: FSTX)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
F-star Therapeutics, Inc.(FSTX)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)